Potential value of PCSK9 inhibitor in ischemic stroke

VernacularTitle:PCSK9抑制剂在缺血性脑卒中的潜在应用价值分析
Author: Xun XU ¹ ; Qingwen JIN ; Renliang ZHANG
Author Information

1. 南京医科大学附属逸夫医院神经内科，南京　211100
Keywords: Ischemic stroke; PCSK9 inhibitor; Atherosclerosis; Low-density lipoprotein cholesterol
From: Chinese Journal of Neuromedicine 2024;23(10):1038-1042
CountryChina
Language:Chinese
Abstract: Stroke has characteristics of high incidence, disability, mortality and recurrence rates. Ischemic stroke (IS) is the most prevalent type of stroke. Early management of risk factors associated with IS, such as cholesterol level, has a beneficial impact on improving long-term prognosis. Proprotein converting enzyme subtilin kexin type 9 (PCSK9) is a circulating enzyme that regulates low density lipoprotein receptor (LDLR), and PCSK9 inhibitor can reduce serum low density lipoprotein cholesterol by blocking the PCSK9 binding to LDLR; therefore, PCSK9 inhibitor, as a new type of lipid-lowering drug, shows great potential in IS prevention and treatment. This article summarizes the physiological functions of PCSK9, clinical application of PCSK9 inhibitor and role of PCSK9 inhibitor in IS pathologic, aiming to offer novel suggestions for improving short-term and long-term prognoses of individuals with IS.